Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Emily Nash

Dr Emily Nash

Abnormal Liver Function Test

Prof Andrew Sindone AM

Prof Andrew Sindone AM

Heart Failure Exacerbation – Important Management Steps After Hospital Discharge

Prof Michelle Giles OAM

Prof Michelle Giles OAM

Practical Strategies to Address Falling Vaccination Rates in Mums and Bubs

Prof Richard Harvey

Prof Richard Harvey

Recurrent Nasal Polyps Management – When to Refer

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022